Skip to main content
    P

    Pacific Biosciences of California (PACB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.84
    -0.12 (-6.12%)

    Market Cap: $611.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pacific Biosciences of California (PACB) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Pacific Biosciences of California (PACB) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Pacific Biosciences of California reported EPS of -$0.11, above the -$0.13 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -0.78%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.13 - -$0.11
    10 analysts
    Revenue Consensus
    $42.55M
    Range$38.81M - $49.35M
    10 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.10
    Range-$0.13 - -$0.09
    5 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.11+4.8%
    60d ago-$0.11+4.8%
    30d ago-$0.11+3.7%
    7d ago-$0.11+3.7%
    Current-$0.10
    Revenue Consensus
    $40.62M
    Range$38.80M - $42.29M
    6 analysts

    Next Report

    PACB has an expected report date of Feb 9, 2027.

    PACB Earnings Call

    The latest PACB earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PACB beat 18, missed 13 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $40.56M, up 5.5% from $38.44M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.11-$0.13-$0.14 - -$0.12+15.38%BeatN/A70 up, 1 downNov 4, 2026$40.56M
    Jun 30, 2026-$0.14-$0.14-$0.14 - -$0.120.00%In lineN/A52 up, 1 downAug 3, 2026$39.01M
    Mar 31, 2026-$0.12-$0.13-$0.17 - -$0.11+7.69%BeatN/A70 up, 1 downMay 7, 2026$37.18M
    Dec 31, 2025-$0.12-$0.13-$0.15 - -$0.12+7.69%BeatN/A80 up, 1 downFeb 12, 2026$44.65M
    Sep 30, 2025-$0.12-$0.16-$0.16 - -$0.12+25.00%BeatN/A76 up, 0 downNov 5, 2025$38.44M
    Jun 30, 2025-$0.13-$0.18-$0.18 - -$0.14+27.78%BeatN/A92 up, 0 downAug 7, 2025$39.77M
    Mar 31, 2025-$0.15-$0.19-$0.20 - -$0.17+21.05%BeatN/A101 up, 2 downMay 8, 2025$37.15M
    Dec 31, 2024-$0.20-$0.17-$0.21 - -$0.11-17.65%MissN/A101 up, 1 downFeb 13, 2025$39.22M
    Sep 30, 2024-$0.17-$0.21-$0.30 - -$0.16+19.05%BeatN/A121 up, 0 downNov 7, 2024$39.97M
    Jun 30, 2024-$0.20-$0.22-$0.29 - -$0.19+9.09%BeatN/A130 up, 0 downAug 7, 2024$36.01M
    Mar 31, 2024-$0.26-$0.26-$0.32 - -$0.230.00%In lineN/A134 up, 0 downMay 9, 2024$38.81M
    Dec 31, 2023-$0.27-$0.28-$0.35 - -$0.24+3.57%BeatN/A152 up, 1 downFeb 15, 2024$58.36M
    Sep 30, 2023-$0.27-$0.29-$0.66 - -$0.26+6.90%BeatN/A102 up, 0 downOct 30, 2023$55.69M
    Jun 30, 2023-$0.26-$0.31-$0.36 - -$0.29+16.13%BeatN/A110 up, 0 downAug 2, 2023$47.57M
    Mar 31, 2023-$0.31-$0.33-$0.39 - -$0.29+6.06%BeatN/A80 up, 0 downMay 2, 2023$38.90M
    Dec 31, 2022-$0.37-$0.36-$0.40 - -$0.34-2.78%MissN/A80 up, 0 downFeb 16, 2023$27.35M
    Sep 30, 2022-$0.32-$0.33-$0.36 - -$0.31+3.03%BeatN/A60 up, 0 downNov 7, 2022$32.31M
    Jun 30, 2022-$0.34-$0.34-$0.37 - -$0.240.00%In lineN/A62 up, 0 downAug 3, 2022$35.47M
    Mar 31, 2022-$0.37-$0.32-$0.33 - -$0.22-15.63%MissN/A60 up, 0 downMay 4, 2022$33.17M
    Dec 31, 2021-$0.30-$0.29-$0.29 - -$0.28-3.45%MissN/A6N/AFeb 15, 2022$36.02M
    Sep 30, 2021-$0.23-$0.24-$0.24 - -$0.21+4.17%BeatN/A4N/ANov 2, 2021$34.89M
    Jun 30, 2021-$0.21-$0.21-$0.22 - -$0.180.00%In lineN/A5N/AAug 3, 2021$30.61M
    Mar 31, 2021-$0.45-$0.31N/A-45.16%MissN/A5N/AApr 29, 2021$29.00M
    Dec 31, 2020-$0.12-$0.12-$0.13 - $0.450.00%In lineN/A5N/AFeb 10, 2021$27.14M
    Sep 30, 2020-$0.14-$0.13-$0.15 - -$0.13-7.69%MissN/A5N/ANov 2, 2020$19.08M
    Jun 30, 2020-$0.15-$0.18-$0.23 - -$0.14+16.67%BeatN/A3N/AAug 3, 2020$17.08M
    Mar 31, 2020-$0.21-$0.15-$0.18 - -$0.14-40.00%MissN/A4N/AMay 6, 2020$15.60M
    Dec 31, 2019-$0.11-$0.14-$0.18 - -$0.14+21.43%BeatN/A3N/AFeb 6, 2020$27.93M
    Sep 30, 2019-$0.17-$0.15-$0.17 - -$0.13-13.33%MissN/A4N/ANov 7, 2019$21.91M
    Jun 30, 2019-$0.14-$0.14-$0.19 - -$0.120.00%In lineN/A4N/AAug 6, 2019$24.62M
    Mar 31, 2019-$0.16-$0.16-$0.20 - -$0.130.00%In lineN/A5N/AMay 3, 2019$16.43M
    Dec 31, 2018-$0.21-$0.13-$0.15 - -$0.12-61.54%MissN/A5N/AFeb 11, 2019$19.53M
    Sep 30, 2018-$0.19-$0.15-$0.17 - -$0.13-26.67%MissN/A7N/ANov 1, 2018$18.16M
    Jun 30, 2018-$0.17-$0.17-$0.18 - -$0.150.00%In lineN/A5N/AAug 2, 2018$21.58M
    Mar 31, 2018-$0.20-$0.19-$0.20 - -$0.18-5.26%MissN/A6N/AMay 2, 2018$19.36M
    Dec 31, 2017-$0.18-$0.20-$0.21 - -$0.18+10.00%BeatN/A6N/AFeb 1, 2018$24.93M
    Sep 30, 2017-$0.19-$0.19-$0.23 - -$0.180.00%In lineN/A6N/ANov 2, 2017$23.55M
    Jun 30, 2017-$0.26-$0.24-$0.26 - -$0.22-8.33%MissN/A6N/AAug 2, 2017$20.07M
    Mar 31, 2017-$0.26-$0.23N/A-13.04%MissN/AN/AN/AApr 26, 2017$24.91M
    Dec 31, 2016-$0.21-$0.23N/A+8.70%BeatN/AN/AN/AFeb 2, 2017$25.72M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.52, after -$0.83 the year before. It was -$0.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.52N/A
    Dec 31, 2024-$0.83N/A
    Dec 31, 2023-$1.11N/A
    Dec 31, 2022-$1.40N/A
    Dec 31, 2021-$1.19N/A
    Dec 31, 2020-$0.62N/A
    Dec 31, 2019-$0.58N/A
    Dec 31, 2018-$0.77N/A
    Dec 31, 2017-$0.89N/A
    Dec 31, 2016-$0.84N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,600 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,6129
    2026Q2Jun 30, 20266,44313
    2026Q1Mar 31, 20265,7459
    2025Q4Dec 31, 20259,18912
    2025Q3Sep 30, 20256,33212
    2025Q2Jun 30, 20256,97412
    2025Q1Mar 31, 20252,6219
    2024Q4Dec 31, 20245,21411

    2026Q3 Earnings Call

    Opening remarks

    Marissa Bych Investor Relations Good afternoon, and welcome to PacBio's third quarter 2026 earnings conference call. With me today are Mark Van Oene, President and Chief Executive Officer; and Bill Meyer, Chief Accounting Officer. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K available on the Securities and Exchange Commission website, www.sec.gov. A copy of our earnings presentation is also available on the Investors section of our website. On today's call, we will make forward-looking statements, including, among others, statements providing predictions, estimates, expectations, and guidance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual results to differ materially from those projected or discussed. Please review our SEC filings, including our most recent Form 10-Q and 10-K and our press release, to better understand the risks and uncertainties that could cause results to differ. We disclaim any obligation to update or revise these forward-looking statements, except as required by law. We also present certain financial information on a non-GAAP basis, which is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Reconciliations between historical U.S. GAAP and non-GAAP results are presented in our earnings release, which is available on the Investors section of our website. For future periods, we're unable to reconcile non-GAAP gross margin and non-GAAP operating expenses without unreasonable effort because certain items that impact these measures, including restructuring and related charges, settlement charges, and costs related to the disposition of short-read assets, are out of our control or cannot be reasonably predicted at this time, and their probable significance cannot be determined. A recording of today's call will be available shortly after the live call in the Investors section of our website. Those electing to use the replay are cautioned that forward-looking statements may differ or change materially after the completion of the live call. And with that, I will turn the call over to Mark.

    Mark Van Oene President and CEO Thank you, and good afternoon, everyone. In the third quarter, we continued the launch of SPRQ-Nx chemistry. Over half of Revio consumable revenue came from customers using SPRQ-Nx. By quarter-end, two-thirds of our Revio installed base had opted to upgrade their software. Adoption continues to climb globally, and we expect the vast majority of the installed base to opt in by year-end. SPRQ-Nx is also driving higher utilization. Some customers are running the same pool of samples three times.

    Frequently Asked Questions About PACB

    When is Pacific Biosciences of California's next earnings date?

    Pacific Biosciences of California's next earnings report is expected for Feb 9, 2027.

    Did PACB beat earnings estimates last quarter?

    Yes. Pacific Biosciences of California reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.13 estimate, a 15.38% surprise.

    What EPS do analysts expect from PACB next quarter?

    The consensus EPS estimate for Pacific Biosciences of California for the quarter ending Dec 31, 2026 is -$0.13 from 10 analysts, with estimates from -$0.13 to -$0.11.

    How often does PACB beat earnings estimates?

    Pacific Biosciences of California beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +10.87%.